The FDA unveiled plans to reduce reliance on animal testing within 3-5 years for drug development, emphasizing the adoption of human-relevant methods such as organoids, organ-on-a-chip, and AI-based computational models. The move follows Congressional authorization allowing alternative data for regulatory decisions, aiming to improve drug safety evaluation, cut costs, and spare animal lives. While challenging, advances in technology and regulatory shifts represent a paradigm change promising faster, more predictive drug assessment without animal models.